CYP1A1 Ile 462Val is a risk factor for ovarian cancer development

Cytokine

Volumn 58, Issue 1, 2012, Pages 73-78

  Huang, Miaoling ^a   Chen, Qing ^a   Xiao, Jianpeng ^b,c   Zhao, Xiaomiao ^a   Liu, Changhao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Institute of Public Health   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

CYP1A1; Meta analysis; Ovarian cancer; Polymorphism; Risk

Indexed keywords

CYTOCHROME P450 1A1; ISOLEUCINE; VALINE; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER INVASION; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; CYP1A1 GENE; DOMINANT GENE; ETHNICITY; GENE; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MSP1 GENE; OVARY CANCER; PRIORITY JOURNAL; PUBLISHING; RECESSIVE GENE; RISK FACTOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; METABOLISM; OVARY TUMOR; RISK; RISK ASSESSMENT;

AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; DEOXYRIBONUCLEASE HPAII; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ODDS RATIO; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 84857450039     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.12.025     Document Type: Article

References (45)

1. Auranen A., Song H., Waterfall C., Dicioccio R.A., Kuschel B., Kjaer S.K., et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 2005, 117:611-618.
2. Song H., Ramus S.J., Quaye L., DiCioccio R.A., Tyrer J., Lomas E., et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 2006, 27:2235-2242.
3. Gayther S.A., Song H., Ramus S.J., Kjaer S.K., Whittemore A.S., Quaye L., et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007, 67:3027-3035.
4. Goode E.L., Fridley B.L., Vierkant R.A., Cunningham J.M., Phelan C.M., Anderson S., et al. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18:935-944.
5. Mikhailova O.N., Gulyaeva L.F., Prudnikov A.V., Gerasimov A.V., Krasilnikov S.E. Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 2006, 6:189-193.
6. Leite D.B., Junqueira M.G., de Carvalho C.V., Massad-Costa A.M., Goncalves W.J., Nicolau S.M., et al. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids 2008, 73:676-680.
7. Nebert D.W., Gonzalez F.J. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987, 56:945-993.
8. Martucci C.P., Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993, 57:237-257.
9. Yager J.D., Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996, 36:203-232.
10. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000, 67-73.
11. Hayashi S., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 1991, 110:407-411.
12. Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990, 263:131-133.
13. Goodman M.T., McDuffie K., Kolonel L.N., Terada K., Donlon T.A., Wilkens L.R., et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001, 10:209-216.
14. Aktas D., Guney I., Alikasifoglu M., Yuce K., Tuncbilek E., Ayhan A. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 2002, 86:124-128.
15. Sugawara T., Nomura E., Sagawa T., Sakuragi N., Fujimoto S. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer 2003, 13:785-790.
16. Terry K.L., Titus-Ernstoff L., Garner E.O., Vitonis A.F., Cramer D.W. Interaction between CYP1A1 polymorphic variants and dietary exposures influencing ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2003, 12:187-190.
17. Seremak-Mrozikiewicz A., Drews K., Semczuk A., Jakowicki J.A., Mrozikiewicz P.M. CYP1A1 alleles in female genital cancers in the polish population. Eur J Obstet Gynecol Reprod Biol 2005, 118:246-250.
18. Sellers T.A., Schildkraut J.M., Pankratz V.S., Vierkant R.A., Fredericksen Z.S., Olson J.E., et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2536-2543.
19. Holt S.K., Rossing M.A., Malone K.E., Schwartz S.M., Weiss N.S., Chen C. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 2007, 16:481-489.
20. Delort L., Chalabi N., Satih S., Rabiau N., Kwiatkowski F., Bignon Y.J., et al. Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 2008, 28:3079-3081.
21. Gulyaeva L.F., Mikhailova O.N., PustyInyak V.O., Kim I.T., Gerasimov A.V., Krasilnikov S.E., et al. Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 2008, 617:359-366.
22. Zhang A.C., Leng W.C., Bai S.F., Bai Z.L. Polymorphism analysis of CYP1A1 Msp1 in ovarian cancer. J Jilin Univ (Med Ed) 2008, 34:499-502.
23. Kotsopoulos J., Vitonis A.F., Terry K.L., De Vivo I., Cramer D.W., Hankinson S.E., et al. Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 2009, 20:335-344.
24. Liu F., Yang C.J. Association between CYP1A1 Ile/Val polymorphisms and ovarian cancer risk. J Hebei North Univ (Med Ed) 2010, 27:29-30.
25. Zhu Z.Y., Mu Y.Q., Fu X.M., Zhao F.X. Relationship between CYP1A1 gene polymorphism and susceptibility of ovarian cancer. Chin J Cancer Prev Treat 2010, 17:1325-1327.
26. 462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 2010, 18:343-347.
27. Goode E.L., White K.L., Vierkant R.A., Phelan C.M., Cunningham J.M., Schildkraut J.M., et al. Xenobiotic-metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 2011, 50:397-402.
28. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
29. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
30. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
31. Egger M., Davey S.G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
32. Zheng Y., Wang J.J., Sun L., Li H.L. Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Mol Biol Rep 2011, [Epub ahead of print].
33. Sergentanis T.N., Economopoulos K.P. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122:459-469.
34. Sergentanis T.N., Economopoulos K.P., Choussein S., Vlahos N.F. Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 2011, 21:323-331.
35. Pan Z., Trikalinos T.A., Kavvoura F.K., Lau J., Ioannidis J.P. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005, 2:e334.
36. Gulden C., Olopade O.I. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol 2010, 194:309-310.
37. Jordan S.J., Whiteman D.C., Purdie D.M., Green A.C., Webb P.M. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006, 103:1122-1129.
38. Fasching P.A., Gayther S., Pearce L., Schildkraut J.M., Goode E., Thiel F., et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009, 3:171-181.
39. Beral V., Doll R., Hermon C., Peto R., Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008, 371:303-314.
40. Schwarz D., Kisselev P., Schunck W.H., Chernogolov A., Boidol W., Cascorbi I., et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics 2000, 10:519-530.
41. Napoli N., Villareal D.T., Mumm S., Halstead L., Sheikh S., Cagaanan M., et al. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 2005, 20:232-239.
42. Gorai I., Inada M., Morinaga H., Uchiyama Y., Yamauchi H., Hirahara F., et al. CYP17 and COMT gene polymorphisms can influence bone directly or indirectly through their effects on endogenous sex steroids, in postmenopausal Japanese women. Bone 2007, 40:28-36.
43. Lurie G., Maskarinec G., Kaaks R., Stanczyk F.Z., Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2005, 14:1521-1527.
44. Kristensen V.N., Tsalenko A., Geisler J., Faldaas A., Grenaker G.I., Lingjaerde O.C., et al. Multilocus analysis of SNP and metabolic data within a given pathway. BMC Genomics 2006, 7:5.
45. Minelli C., Thompson J.R., Tobin M.D., Abrams K.R. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol 2004, 160:445-452.